SANSIA OY has floated a tender for Regenheart Research Edc System. The project location is Finland and the tender is closing on 04 Apr 2019. The tender notice number is 230119, while the TOT Ref Number is 31698791. Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.

Expired Tender

Procurement Summary

Country : Finland

Summary : Regenheart Research Edc System

Deadline : 04 Apr 2019

Other Information

Notice Type : Tender

TOT Ref.No.: 31698791

Document Ref. No. : 230119

Competition : ICB

Financier : Self Financed

Purchaser Ownership : -

Tender Value : Refer Document

Purchaser's Detail

Purchaser : SANSIA OY
Procurement entity: Sansia Oy
Business ID: 2364760-8
Contact: Mari Jskelinen
Mailing address: PL 2000, Viestikatu 3 Postcode: 70600
Town / City: Kuopio
Country: Finland
Phone: 358447182933
Email address: mari.jaaskelainen@sansia.fi by Internet address(URL): https://www.sansia.fi by
Finland
Email :mari.jaaskelainen@sansia.fi
URL :www.sansia.fi

Tender Details

Tender are invited for Regenheart Research Edc System
The Subject Of The Acquisition :
Purchase Name: EDG System for ReGenHeart Research
Reference or reference number of the acquisition: 230119
Description of Acquisition: Acquisition of Electronic Data Capture (EDC) for Clinical Phase II (Phase II) Pharmaceutical Research (ReGenHeart)such as the proper management of data collected in the system (Data Management) and the training of the system for its users. The data obtained during the study is stored in the EDC system, so that the results obtained during the study can be considered to be the sameand the conclusions drawn from them are correct. Researchers recruited for research do not participate in data entry into the EDC system. The EDC system is acquired for the ReGenHeart study, which receives support from the European Union's Horizon 2020 program. ReGenHeart is randomized, cervicala nocturnal and placebo-controlled study investigating the efficacy and safety of gene therapy (AdVEGF-DdNdC) in the treatment of unresponsive and unconventional coronary artery disease (refractory angina pectoris). investigation180 patients from six European hospitals: Finland, UK, Spain, Poland (2 different centers) and Denmark (30 patients per center). The study is scheduled to end on December 31, 2023. For a more detailed description of the starting point, expense of the ReGenHeart studyand the measures to be taken, the tenderer is invited to consult the research plan annexed to this invitation to tender.
Acquisition exceeds the threshold of section 25 of the Procurement Act: Yes
Main Objective: Main nomenclature Information processing services. (72310000-1)
The main realization of the acquisitionlocation: North Savo (FI1D2)
Duration of the contract: -
Procurement procedure :
Procurement procedure: Open procedure
The procedure establishes a framework agreement: No
Electronic auction is used for competitive tendering: No
Sub-tenders accepted: No
Alternative offers accepted: No
Purchase is reserved for work centers or completedwork programs: No
Deadline : 4.4.2019 16:00

Documents

 Tender Notice